DETROIT, Mich. – Investigators from the C.S. Mott Center for Human Growth and Development at the Wayne State University School of Medicine reported today in a publication in Cancer Immunology Research the characterization of a novel therapeutic approach capable of restoring immune surveillance and providing long-term protection against ovarian cancer...
Latest News
As the mom of a 16-year-old daughter with a rare disease, I’ve had to learn how to accommodate Grace’s limitations. Many daily activities became much harder after she was diagnosed with Lambert-Eaton myasthenic syndrome (LEMS). My goal is to make her life with LEMS as easy as possible, so I began researching how...
Alzheimer’s disease is a devastating brain illness that affects an estimated 47 million people worldwide. It is the most common cause of dementia in the Western world. Despite this, there are currently no treatments that are effective in curing Alzheimer’s disease or preventing its relentless progression. Alzheimer’s disease is caused...
It was a landmark day they never expected to celebrate. Tristan Hall’s family were told he would not reach his first birthday – so they were delighted when he not only surpassed that but is now the proud owner of his first tooth. The brave tot celebrated his birthday in...
WASHINGTON DC – Gene-editing technologies are progressing fast, and there are now more than 100 ongoing trials for new therapies and diagnostics based on CRISPR-Cas, zinc finger nucleases, TALENS, and base editors. While most of these trials are evaluating ex vivo gene-edited cell-based therapies for cancers and genetic blood disorders,...
COPENHAGEN, Denmark — Ascendis Pharma A/S (Nasdaq: ASND) today announced topline results from Week 52 of COACH, the first Phase 2 clinical trial to evaluate combination therapy with once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. At Week 52, combination therapy showed durable growth without...
Guildford, England. Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to research from the University of Surrey. The results of the year-long phase 3 clinical trial could revolutionise the future...
MISSISSAUGA, Ontario – Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with Conditions (NOC/c)] for Wegovy® (semaglutide injection) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).1 Authorization in Canada...
PLAINSBORO, N.J. — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy® (semaglutide) injection 2.4 mg, making it the first and only glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but...
Bristol, England – A weight loss intervention in people with type 2 diabetes was found to alter levels of cancer-related proteins, according to the findings of a new University of Bristol-led study. The study, published in eBioMedicine, is the first to show that weight loss in people recently diagnosed with...